Skip to main content
Explore URMC

Ovarian Cancer: Tesaro-FIRST

Research Question:
Does the drug TSR-042 help the survival of patients with ovarian cancer?

Basic Study Information

The purpose of this study is to compare the progression-free survival of patients with Stage III or IV non-mucinous epithelial ovarian cancer treated with platinum-based therapy, TSR-042, and niraparib to standard-of-care (SOC) platinum-based therapy.

Study Reference #: IGYO18058

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Moore

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search